3 New Strong Buy Ratings from Top-Rated Analysts: 02/06/2026

Here’s the latest from our most popular screener — fantastic stock picks to check out before the market closes…

• Halozyme Therapeutics (HALO): Biotech breakout fueled by raised guidance 
• Amphenol Corp. (APH): Elite connectors leader dips into buy zone 
• Carpenter Technology (CRS): Aerospace metals powerhouse with unanimous buy calls

P.S. Want more hot stock picks? Check out these 2 high-upside tech stocks to buy now.

 

A note from our sponsors...

1. Amphenol Corp (NYSE: APH)

Despite a recent pullback following earnings, this electronic and fiber optic cable company's robust Q4 results and solid 2026 guidance have attracted strong analyst support, with the stock trading at a compelling entry point.

Zen Rating: Buy (B) — see full analysis

Recent Price: $133.63 — get current quote

Max 1-year forecast: $185.00

Why we're watching:

• Analyst support: Among the 10 analysts we track issuing ratings on the stock, APH enjoys 8 Strong Buy and 2 Buy ratings — very bullish indeed. See the ratings.
• Citigroup's Asiya Merchant (a top 1% rated analyst) recently maintained her Strong Buy rating with a $180 price target, emphasizing Amphenol's innovative technologies and expanding product lines that cater to critical defense and telecommunications sectors.
• JP Morgan analyst Samik Chatterjee (a top 1% rated analyst) reaffirmed his Strong Buy rating at $185, highlighting the company's strong financial fundamentals, optimal operations, and superior earnings potential driven by operational efficiency and cost structure advantages. 
• Industry ranking context: APH is currently ranked in the top third of the A-rated Electric Components Industry.
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr — APH ranks in the 83rd percentile of the 4,600+ stocks we track overall.
• Component Grades: APH demonstrates exceptional quality with above-average B Component Grades in several key areas: Growth, Momentum, Sentiment, and Financials. See all 7 Zen Component Grades here

2. Carpenter Technology (NYSE: CRS)

This company manufactures stainless steel and corrosion-resistant alloys for a variety of high-demand industries: aerospace and defense, industrial, medical, transportation, and energy. Following strong Q2 2026 earnings that beat estimates with revenues rising 8% year-over-year, the company has attracted universal Strong Buy ratings from all five covering analysts.

Zen Rating: Buy (B) — see full analysis

Recent Price: $328.54 — get current quote

Max 1-year forecast: $400.00

Why we're watching:

• Analyst support: 5 analysts cover CRS with unanimous 5 Strong Buy ratings and a max price target that suggests nearly 20% upside in the coming year. See the ratings
• KeyBanc analyst Philip Gibbs (a top 1% rated analyst) recently upgraded CRS to Strong Buy with a $380 price target, signaling increased confidence in the company's strategic direction and aerospace and defense growth prospects.
• Jones Trading's Josh Sullivan (a top 1% rated analyst) initiated coverage with a Strong Buy rating and the highest price target of $400, citing the company's strong fundamentals and market leadership position.  
• Industry ranking context: CRS is currently the 4th highest-rated stock out of 15 in the Metal Fabrication industry, which has an excellent Industry Rating of A, placing it among top performers in a thriving sector.
• Zen Rating highlights: As a B-rated stock, CRS is in a class of equities that have historically delivered market-beating returns over the past 20+ years. 
• Component Grades: CRS posts several outstanding grades including As for Safety (and Financials and a B for Momentum, suggesting a lower-risk company with a solid balance sheet that might not be “boring” for long. See all 7 Zen Component Grades here

3. Halozyme Therapeutics (NASDAQ: HALO)

This is sort of like a biopharma technology platform company, with products based on its proprietary enzyme technology that enables subcutaneous delivery of injectable biologics. The company is gaining momentum following strong preliminary 2025 results and raised 2026 guidance, positioning it as a standout value opportunity in the biotech sector.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $77.30 — get current quote

Max 1-year forecast: $92.00

Why we're watching:

• Analyst support: 9 analysts cover HALO. It has 3 Strong Buy, 3 Buy, and 3 Hold ratings, reflecting an overall Buy consensus. See the ratings
• Citizens researcher Jason Butler (a top 2% rated analyst) recently maintained a Buy rating with a $92 price target following strong growth projections in key therapeutic areas, highlighting positive clinical trial outcomes and rising investor confidence.
• HC Wainwright & Co. analyst Mitchell Kapoor (a top 5% rated analyst) reaffirmed his Buy rating at $75, emphasizing robust market demand for HALO's therapies and the company's strategic focus on expanding existing product reach through valuable partnerships.  
• Industry ranking context: HALO is currently the 13th highest-rated stock out of 482 in the Biotech industry — indicating it could be an exceptional pick within a troubled industry (Industry Rating: F).
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — HALO ranks in this elite tier, composed of the top 5% of stocks we track.
• Component Grades: HALO excels with A grades for Value and Financials (not common for a biotech stock), and a strong B from our Artificial Intelligence factor, which sifts through mountains of data to detect subtle patterns that suggest future outperformance that we mere humans might not be able to see. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.